Net Sales Margin: DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Corp - graphic logo of issuer DMAC

The net margin ratio for DiaMedica Therapeutics (DMAC) on GURU.Markets reflects the company's pricing power in implementing blood flow restoration therapy, where the value 0.00 represents the latest figure. The brand is valued for the safety of its molecules in treating kidney failure and strokes. However, business sustainability relies on the patents for the drug DM199, the success of which depends directly on the results of ongoing clinical trials.

DiaMedica Corp (DMAC) Return on Sales by Net Profit: for the period 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for DiaMedica Pharma (DMAC)

- company stock exchange capitalization indicators:
Analysis of all company metrics:DiaMedica Therapeutics Inc - DMAC
Flagship merchandise of DiaMedica Therapeutics Inc

For DiaMedica Therapeutics (DMAC), whose model relies on R&D without current sales, the final sales margin indicator on GURU.Markets demonstrates the efficiency of operating expense management relative to available income. This metric is calculated as the ratio of net income to revenue, reflecting the business's ability to generate free cash flow and protect capital from cost inflation prior to the commercialization of the drug.